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OBJECTIVES: To evaluate whether infliximab, a modern off-label biologic, is cost-
effective for treating sarcoid posterior uveitis compared to methotrexate and sys-
temtic steroids. Sarcoid posterior uveitis is a progressive eye disease that can lead
to blindness if untreated. Ophthalmologists have utilized infliximab, a TNF-alpha
inhibitor, which reverses effects of uveitis. METHODS: A semi-Markov model fol-
lowed patients’ therapy from the onset of sarcoid posterior uveitis using the soci-
etal perspective. The lifetime model simulated health states that could lead to
successful reversal of uveitis with standard or intensified treatment with systemic
steroids, methotrexate, or infliximab. Probabilities, health utilities, and costs were
included in the model based on findings from literature. Costs and effects were
discounted at 3% ($US; 2010 values). We conducted univariate sensitivity analyses,
threshold analyses, and a Bayesian multivariate probablistic sensitivity analysis
using 10,000 Monte Carlo simulations. Results were interpretted from a predeter-
mined willingness-to-pay of $50,000/QALY. RESULTS: In order of cost, base case
results showed systemic steroids most affordable ($26,871; 14.58 QALYs), followed
by methotrexate ($40,351; 15.92 QALYs), and then infliximab ($46,547; 15.04
QALYs). Methotrexate was cost-effective compared to steroids, with an incremen-
tal cost-effectiveness ratio of $10,053/QALY. Methotrexate dominated infliximab.
Univariate sensitivity analyses suggested that the model was sensitive to the utility
of a patient’s successful recovery from uveitis (0.84 QALYs). If patients’ health
utility after successful recovery is below 0.750, then infliximab has a greater net
benefit than methotrexate. The multivariate probabilistic sensitivity analysis
showed that methotrexate dominated infliximab in 60% of the simulations.
CONCLUSIONS: This cost-effectiveness analysis suggests that despite major ad-
vances in the use of biologics for treating sight-threatening sarcoid posterior uve-
itis, methotrexate remains a less expensive and more cost-effective strategy. Meth-
otrexate should be adopted as the standard of care for treatment considering its
incremental cost-effectiveness at a reasonable willingness-to-pay. Other thera-
peutic options, such as infliximab, may be considered for certain cases.
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OBJECTIVES: Pharmacoeconomic analyses (PEs) were performed in five European
countries to determine costs, consequences and cost effectiveness of a partially
hydrolysed 100% whey-based infant formula, manufactured by Nestlé S.A, Swit-
zerland (PHF-W) in the prevention of atopic dermatitis (AD) in ‘at risk’ children
when compared to standard cow’s milk formula (SF) or extensively hydrolyzed
formula (EHF). METHODS: The PEs were performed in France, Germany, Spain,
Denmark and Switzerland, using decision-analytic models depicting AD treatment
pathways, as well as resource utilisation and costs associated with the treatment of
AD in healthy yet ‘at risk’ newborns who could not be exclusively breastfed. A time
horizon of 12 months including 6 months of formula consumption was applied,
with country-specific resource use and costs. In four settings, SF was the main
comparator and the final outcome of the PEs was the incremental cost per avoided
case (ICER) of AD when comparing subjects who used PHF-W versus SF. Given a lack
in significant differences in efficacy between PHF-W and EHF, a cost-minimization
approach was used in all settings to compare these formulas. Three perspectives
were applied: the Ministry of Health (MOH), the family and society. RESULTS: The
analyses of PHF-W vs. SF generated ICERs ranging from €801 to €1343 (MOH), from
-€1796 to -€454 (family) and from -€995 to €719 (society). The costs of formula and
time loss were the most important cost drivers. In the analyses of PHF-W versus
EHF in prevention, PHF-W demonstrated savings ranging from €4-€120 million, or
€1.3-€64 million for the MOH perspective. The robustness of the models and the
direction of the results were confirmed by one-way and probabilistic sensitivity
analyses. CONCLUSIONS: In five European countries, PHF-W appears to be the
product best positioned in prevention at a reasonable cost when compared to SF
and with important cost-savings versus EHF.
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OBJECTIVES: To evaluate cost-effectiveness of ustekinumab vs etanercept for se-
vere psoriasis in Russia. METHODS: Cost-effectiveness analysis was performed.
The data about efficacy and safety of biologic agents was analyzed. Cost-effective-
ness ratio (CER) was calculated for ustekinumab and etanercept. Pharmaceutical
costs were taken into account only. Achievement of PASI 75 was a criterion of
efficacy, data about it was extracted from 12 weeks comparative clinical trial.
RESULTS: The efficacy of ustekinumab was higher than etanercept in a direct
comparative trial (67.5 and 56.8% of patients achieved PASI 75 by week 12 respec-
tively). Both biologic agents were generally well tolerated in most patients. Usteki-
numab was a bit less costly than etanercept: 470.00 and 496.62 thousands rub (16.92
and 17.88 thousands $) for 12-weeks treatment respectively. Therefore CER was
more favorable for ustekinumab than for etanercept: 696.30 thousands rub (25.06
thousands $) and 874.33 thousands rub ($31.47 thousands $) per patient with PASI
75 achieved respectively. CONCLUSIONS: Ustekinumab is a dominanting alterna-
tive to etanercept for patients with severe psoriasis in Russia.
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OBJECTIVES: Ozurdex (dexamethasone 700 g intravitreal implant in applicator)
was the first EMA licensed pharmacotherapy for macular oedema following central
and branch retinal vein occlusion (CRVO, BRVO), a leading cause of vision loss. The
objective of this analysis was to evaluate the cost-effectiveness of Ozurdex com-
pared with a strategy of observation for the treatment of macular oedema (ME)
following CRVO, and for BRVO patients with macular haemorrhage (BRVO-MH) or
who have failed prior laser treatment (BRVO-PL). The analysis was performed from
a UK NHS perspective. METHODS: A cost-utility model was developed to estimate
the lifetime costs and effects of Ozurdex compared with observation in patients
with CRVO, BRVO-MH and BRVO-PL based on the GENEVA 008 and GENEVA 009
studies. Patients in the model could move between six BCVA defined health states
(best corrected visual acuity) based on the number of letters read correctly on the
Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. Cost data were ob-
tained from literature and NHS reference costs. Utility values ranged between 0.599
and 0.862 and were derived from a preference-based scoring algorithm, the Visual
Function Questionnaire Utility Index (VFQ-UI), valued by members of the general
population using time-trade off (TTO). RESULTS: Ozurdex was shown to be cost-
effective relative to observation with ICERs of £16,522, £17,741 and £6,361 for pa-
tients with CRVO, BRVO-MH and BRVO-PL respectively. One-way sensitivity anal-
ysis demonstrated that the proportion of patients affected in the baseline defined
worse-seeing eye was a key driver of cost-effectiveness. Probabilistic sensitivity
analysis demonstrated that at a threshold of £30,000, Ozurdex was a cost effective
option in 85.2% of simulations for CRVO, 82.1% of simulations for BRVO-MH and
98.2% of simulations for BRVO-PL.CONCLUSIONS:Ozurdex is a cost-effective treat-
ment option from a UK NHS perspective for macular oedema secondary to CRVO,
BRVO-MH and BRVO-PL.
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OBJECTIVES: Ozurdex (dexamethasone 700 g intravitreal implant in applicator)
was the first licensed pharmacotherapy for macular oedema following branch ret-
inal vein occlusion (BRVO) in the UK; however unlicenced use of Bevacizumab
given by intravitreal injection was considered a potential comparator for economic
evaluation. No head to head RCTs exist to compare outcomes; a mixed treatment
comparison (MTC) was performed to synthesise available data. METHODS: A life-
time cost-utility model was produced with a treatment period of up to 3 years.
Patients received an average of 9.96 bevacizumab or 2.24 Ozurdex treatments, 75%
of which were costed based on a day case setting. Efficacy was measured in terms
of letters gained on the Early Treatment of Diabetic Retinopathy Study (ETDRS)
chart. This was estimated from an MTC where the network of evidence included
comparisons of Ozurdex versus observation, observation versus grid laser and grid
laser versus bevacizumab. QALYs were calculated from the letters gained using a
coefficient obtained from regression analysis predicting the Visual Function Ques-
tionnaire Utility Index (VFQ-UI) score from BCVA. Differences in AE profiles were
accounted for within the analysis. RESULTS: The day 180 results of the MTC indi-
cated a difference (pns) in BCVA of 1.74 letters (95% CI -9.57 to 6.19) favouring
bevacizumab; MTC Results at day 60 show this trend to be reversed. The analysis
also demonstrated that an Ozurdex based regimen is less costly than a bevaci-
zumab regimen making the ICER difficult to interpret. Therefore net monetary
benefit (NMB) was calculated to demonstrate an NMB of Ozurdex vs. bevacizumab
(based on day 180 results) of £2,228 at a willingness to pay per QALY of £20,000,
robust to sensitivity analyses. CONCLUSIONS: The results of this analysis indicate
that Ozurdex is a cost-effective treatment for macular oedema following BRVO
when compared with bevacizumab, from a UK NHS perspective.
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OBJECTIVES: Cost-effectiveness models in age-related macular degeneration use
the utilities based on the better-seeing eye, because this mainly influence quality of
life. Most models use the utility as if we only treat better-seeing eyes, although in
trials the majority of the treated eyes are the poorer-seeing eyes. This discrepancy
results in overestimating the QALY. Therefore a correction should be applied. The
objective of this study is to estimate the influence on the (incremental) cost-effec-
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tiveness when correcting for the poorer-seeing eye.METHODS:An existing Markov
model comparing three treatment frequencies of Bevacizumab (Avastin) is used, to
investigate the effect of the correction of the poorer-seeing eye. We examined
several scenarios of the poorer-seeing eye; no influence(0%), 10% and 20% influence
of the utility of the better-seeing eye. In addition, it can be argued that treating the
poorer-seeing eye has a preventive function, as it can become the future better-
seeing eye. In the model a switch of the better-seeing eye is assumed after two and
four years. RESULTS: By including the correction of the utility of the poorer-seeing
eye the incremental cost-effectiveness ratio’s (ICER) change from €5,260, €31,167
and €3,712, to respectively €10,375, €60,124 and €7,377 (20% influence). Lowering the
influence from 20% to 0% has an effect of respectively, €13,706, €78,314 and €9,796.
When inserting a switch at two and four years, the ICER reduces from €10,375,
€60,124 and €7.377 to respectively €7,325, €53,649 and €4,848 at four years and
almost half at 2 years. CONCLUSIONS: The results show that overestimating the
QALY by excluding the poorer-seeing eye results in a lower incremental cost-effec-
tiveness. Poorer-seeing eyes should be used when modeling eye-diseases. Whether
the poorer-seeing eye contributes 20%, 10% or 0% has a small impact on the change
in ICER’s. The preventive function of treating the poorer-seeing eye should also be
taken into account.
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OBJECTIVES: To assess the economic burden of unresectable or metastatic (“ad-
vanced”) melanoma. METHODS: Using data from calendar years (CY) 2003-2008
from a large health insurance database and case-finding algorithms that we devel-
oped for use in such data, we identified all persons with Stage III unresectable or
Stage IV melanoma at initial presentation, as well as those who presented with
earlier-stage disease in prior years and progressed to advanced disease (i.e., recur-
rent cases). We tallied health care costs on an all-cause basis for all such persons
alive for one or more day in CY2008. Health care costs were tallied by category of
utilization (e.g., hospitalizations, outpatient visits, outpatient pharmacotherapy,
etc.) as well as on an overall basis. Reimbursed amounts were used as a proxy for
costs. RESULTS: We identified 1527 persons with advanced melanoma in CY2008
(Stage III unresectable, 267; Stage IV, 1260). Stage IV patients were more likely to be
hospitalized during the year than those with Stage III disease (39% vs 26%, respec-
tively; p0.01). Mean (SD) total annual cost per patient was $42,848 ($66,279), and
was higher for those with Stage IV versus Stage III unresectable disease ($45,786 vs
$28,983; p0.01). Outpatient services (including the cost of infused drugs) ac-
counted for approximately 54% of total costs, while hospitalization and outpatient
pharmacotherapy accounted for 37% and 9%, respectively. CONCLUSIONS: Our
findings suggest that the economic burden of advanced melanoma is high, espe-
cially in patients with Stage IV disease.
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OBJECTIVES: Several treatment options are available for psoriasis, an incurable
dermatological condition, but there is limited information on actual treatment
patterns. This retrospective study aimed to provide a snap shot of the use of pso-
riasis medications and recent trends over time in current clinical practice in pso-
riasis patients with co-morbid conditions. METHODS: Adult patients with 2 doc-
umented psoriasis diagnoses (ICD-9 codes: 696.1 were selected from a large US
administrative claims database (2004-2008). The index date was defined as the
latest date with a psoriasis diagnosis. Psoriasis treatments, including topical ther-
apies, phototherapy, conventional systemic therapies, and biologics, were identi-
fied during the 6 months following the index date and described for the entire
psoriasis population, a sub-group of obese patients (body mass index [BMI] 30),
and stratified by index year to examine trends over time. RESULTS: A total of
106,128 psoriasis patients were selected. The mean age was 5215 years and 52%
were female. Overall, 62.3% of psoriasis patients were on topical therapies, 12.1%
used biologics, 7.4% used other immunosuppressant agents, 5.6% used photother-
apy and 27.2% were untreated. Over time, biologic use increased from 8.7% in 2004
to 21.0% in 2008, while the use of other treatments did not show this trend. In the
sub-group of psoriasis patients with BMI information (N1874; 646 obese and 1,228
non-obese), more obese patients were treated with biologics (20.0% vs. 15.0%) and
other immunosuppressant agents (12.4% vs. 6.9%) than non-obese patients.
CONCLUSIONS: The majority of psoriasis patients were treated with topical ther-
apies. There has been an increase in the proportion of patients using biologics in
the recent years. In addition, biologics and other immunosuppressant therapies
were more likely to be used among obese patients.
Sensory Systems Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVES: Evidence is limited on the extent to which health state utility decre-
ments differ between changes in the better-seeing and worse-seeing eyes follow-
ing treatment. This study presents estimates of the utility levels as a function of the
visual acuity in the treated eye stratified by the condition of the fellow (untreated)
eye in patients treated for visual impairment caused by diabetic macular edema
(DME). METHODS: Data from RESTORE clinical trial with (12 months follow up of
ranibizumab treatment for DME) were analyzed. 8 health states were defined by
BCVA in the treated eye. Mean utility was estimated using multivariate regression
(repeated measures analysis). The regression was tested for confounders including
disease severity. The influence of BCVA in the fellow eye on the health index was
explored by separating treated eyes into cohorts according to visual acuity of the
fellow eye: better, equal or worse. Results were compared with other published
studies. RESULTS: The utility ranged from 0.86 (SE0.014) with BCVA 76-100 letters
(Snellen score) to 0.55 (SE0.083) with BCVA 0-25 letters (unadjusted model). Dis-
ease severity had a non-significant effect on this range (p0.05). BCVA of the worse
seeing eye had a significant impact on the utility (utility decrement -0.11 from
76-100 letters to 36-45 letters), with better seeing eyes demonstrating a utility dec-
rement -0.14 from 76-100 letters to 36-45 letters. Results were inconclusive for
health states below 35 letters due to small numbers. CONCLUSIONS: This explor-
ative analysis reveals that visual acuity of a worse seeing eye has a significant
impact on utility and may be comparable to the impact on the better seeing eye.
Importantly, these findings are supported by improvements in quality of life ob-
served using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-
25) for DME patients treated with ranibizumab in the worse seeing eye in RESTORE.
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OBJECTIVES: HRQoL is often impaired in patients with skin diseases but it is often
assessed with different instruments, generating data not directly comparable or
not suitable to estimate utility. Assessing the association between HRQoL mea-
sures obtained with different instruments could be useful to obtain more complete
data. The dermatology life quality index (DLQI) is a condition-specific question-
naire widely used to assess HRQoL in subjects with skin diseases. We aimed to
estimate the association between EQ-5D VAS and utility score with the DLQI sum-
mary score (max 30 and min 0; higher score corresponds to more impaired quality
of life) in patients with severe CHE and refractory to therapy with topical potent
corticosteroids.METHODS:Within a naturalistic, multicentre cost-of-illness study;
patients aged18 years, consecutively accessing at the participating centres, com-
pleted the EQ-5D and DLQI questionnaires during the enrolment visit. Individual
patient utility was estimated from EQ-5D responses using the standard UK scoring
algorithm. A multivariable linear regression model was built to estimate the asso-
ciation between the EQ-5D VAS and utility score with the DLQI summary score,
adjusted for age and gender. The bootstrap resampling was used to calculate stan-
dard errors and 95% confidence intervals. RESULTS: A total of 104 patients (mean
ageSD44.515.0, 39.4% male) were enrolled. DLQI meanSD summary score
was 11.36.3, EQ-5D VAS meanSD60.423.3 and EQ-5D utility
meanSD0.500.31. EQ-5D VAS and utility showed a linear negative relationship
with DLQI summary score. One point rise in DLQI was associated with a EQ-5D VAS
decrease of 1.84 (SE0.34; 95%CI-2.52,-1.16; R20.261) and a utility index decrease
of 0.025 (SE0.005; 95%CI-0.035,-0.014; R20.254) in utility. CONCLUSIONS: DLQI
summary score is significantly associated with the EQ-5D VAS and utility index.
Our results could be useful to derive EQ-5D information from DLQI data, to perform
economic evaluations targeted to patients with severe CHE refractory to therapy
with topical potent corticosteroids.
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OBJECTIVES: The aims of the study were to estimate score ranges associated with
dry eye severity based on the Impact of Dry Eye on Everyday Life (IDEEL) Symptom
Bother (SB) domain, and to evaluate the overall performance of the SB domain.
METHODS: A total of 210 participants (130 dry eye patients, 32 Sjogren’s patients
and 48 controls) completed the IDEEL SB domain and reported their degree of dry
eye severity on an ordinal response scale of none, mild, moderate or severe. Ordinal
regression analysis using a proportional-odds model was used to provide SB cut-off
score ranges associated with the highest probability of membership of each of the
four individual response categories. ROC analysis was used to examine the speci-
ficity and sensitivity of the overall SB scale. RESULTS: Ordinal regression revealed
SB to be a significant predictor of patient-reported dry eye severity (2225.59,
p0.001). Examination of individual probabilities associated with each SB score
revealed that the following score ranges were associated with the highest proba-
bility of membership of each dry eye category: None (0-16), Mild (17-38), Moderate
(39-65), Severe (66). ROC curve analysis revealed excellent performance of the SB
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